Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide‐1
receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

Objectives To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only
orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 …

Objectives To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1)
receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) …

Objectives To update and assess the efficacy and tolerability of once weekly subcutaneous
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …

Background and aims To assess the safety and efficacy of semaglutide compared with
placebo and other anti-hyperglycaemic agents in type 2 diabetes (T2DM). Methods We …

Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …

1 BACKGROUND Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living …

Background Previously, the only available glucagon-like peptide-1 receptor agonists (GLP-1
RA) were injectable. Approval of oral semaglutide (Rybelsus®) represents the first orally …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To …